J&J's RSV Vaccine Candidate Shows 80% Efficacy In Older Adults

Johnson & Johnson's JNJ Janssen announced respiratory syncytial virus (RSV) vaccine candidate's efficacy as high as 80% in preventing severe infections in a mid-stage clinical trial.
Related: Pfizer Starts Late-Stage Trial For RSV Vaccine Candidate In Older Patients.
Janssen revealed the proof-of-concept data at IDWeek Saturday, showcasing a CYPRESS trial in over 5,700 people aged 65 years and up randomized to receive the RSV vaccine candidate or placebo.
The main goal was to prevent the occurrence of lower respiratory tract disease due to RSV infection. Secondary endpoints looked for adverse events, neutralizing antibodies, and other outcomes.
The vaccine also demonstrated an efficacy of 70% against any symptomatic RSV-associated acute respiratory infection (ARI).
Before presenting the data at the conference, Janssen announced that the RSV vaccine would be moved to a phase 3 trial called EVERGREEN based on data from the Phase 2 trial.
This late-stage trial will have 23,000 participants with an expanded age group of 60 and up. Trial volunteers will be tracked for at least two seasons.
Related: Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants.
Price Action: JNJ stock is trading 0.06% higher at $160.54 on the last check Monday.